Fresenius Kabi in talks to buy Akorn

By Gareth Macdonald contact

- Last updated on GMT


Related tags: U.s. securities and exchange commission, Fresenius kabi

Akorn Inc is in takeover talks with German injectable drug specialist Fresenius SE & Co. KGaA.

The US generic drug manufacturer confirmed the talks in a US Securities and Exchange Commission (SEC) filing​ today.

Similarly, Fresenius said​ discussions are ongoing.

A spokesman for the German firm told us "Fresenius Kabi is currently in discussions with Akorn, Inc. concerning a potential acquisition​."

He declined to comment further.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us


View more